免疫检查点抑制剂相关自身免疫性脑炎的系统综述
常见肿瘤为黑色素瘤和非小细胞肺癌(各30%),最常见药物为纳武利尤单抗(61%),中位发病在3个治疗周期后。非边缘性脑炎约为边缘性的两倍,神经元内抗体阳性是一线免疫治疗后未改善的显著预测因素。
要点
- ICPI-AIE多发生于纳武利尤单抗治疗中位3周期后,表现异质。
- 非边缘性脑炎比边缘性脑炎更常见(约两倍,p<0.05)。
- 神经元内抗体阳性预示一线免疫治疗反应差(p<0.05)。
核心结论
- ICPI-AIE是一组异质性疾病,未来神经科医生可能更常遇到。
- 病理生理机制、流行病学和最佳治疗策略仍是未解决的问题。
研究设计与样本
- 系统综述,检索PubMed、Cochrane Library和Embase,遵循PRISMA指南并在PROSPERO预注册。
主要发现
- 患者平均年龄58.6岁,女性占43%。
- 常见肿瘤为黑色素瘤(30%)和非小细胞肺癌(30%),脑转移16例(30%)。
- 最常见ICPI为纳武利尤单抗(61%),中位发病在3.0个治疗周期后。
- 非边缘性AIE约为边缘性AIE的两倍(p<0.05)。
- 常见异常包括MRI双颞叶FLAIR高信号、EEG持续慢波和弥漫性减慢、CSF单核细胞增多。
关键数值与推荐
- 神经元内抗体比神经元表面抗体更常见,且是一线免疫治疗后未改善的显著预测因素(p<0.05)。
临床怎么用
- 神经科医生应认识ICPI-AIE可在治疗早期或晚期出现,表现异质。
- 对ICPI治疗患者出现脑炎症状时,应考虑到ICPI-AIE并完善MRI、EEG和CSF检查。
- 神经元内抗体阳性可能提示一线免疫治疗反应不佳。
局限性
- 仅纳入已发表病例,可能存在报告偏倚。
- 样本量小(54例),证据等级有限。
- 病理生理机制、流行病学和最佳治疗策略尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the clinical and laboratory features of immune checkpoint inhibitor (ICPI)-associated autoimmune encephalitis (ICPI-AIE), an increasingly recognized adverse event with ICPI treatment. METHODS: We searched PubMed, The Cochrane Library, and Embase for ICPI-AIE cases from the first description in 2015 until January 2020 using standard bibliographic measures including PRISMA guidelines and preregistration with PROSPERO. RESULTS: Thirty-nine studies met inclusion criteria, resulting in 54 patients with ICPI-AIE (mean age 58.6 years; 43% female). Common cancers included melanoma (30%) and non-small cell lung cancer (30%). Brain metastases were found in 16 patients (30%). The most frequent ICPI was nivolumab (61%). Onset of ICPI-AIE occurred after a median of 3.0 treatment cycles, but very early and late presentations were common. Nonlimbic AIE was roughly twice as frequent as limbic AIE (p < 0.05). The most common laboratory abnormalities included bitemporal fluid-attenuated inversion recovery lesions on MRI, continuous slow waves and diffuse slowing on EEG, and monocytic pleocytosis on CSF analysis. Intraneuronal antibodies were more frequent than neuronal surface antibodies and a significant predictor for lack of improvement after first-line immunotherapy (p < 0.05). CONCLUSIONS: ICPI-AIE consists of a heterogenous group of conditions. Neurologists will likely encounter ICPI-AIE more often in the future, but important unresolved questions include the pathophysiologic mechanisms, the epidemiology, and the best treatment approaches associated with ICPI-AIE.
引用
- Nersesjan V, McWilliam O, Krarup LH, et al. Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review. Neurology. 2021. PMID: 33952651. doi:10.1212/WNL.0000000000012122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。